The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany Bo DingMarc PignotAndreas Schwarting Original Research Open access 22 January 2024 Pages: 285 - 299
Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis Han XieYuan ZhangWeihong Ge Original Research Open access 18 January 2024 Pages: 269 - 283
Impact of the COVID-19 Pandemic on People Living with Rheumatoid Arthritis: Experiences and Preferences in Accessing Healthcare Across Five Countries Alain SarauxLicia Maria Henrique da MotaMeriem Kessouri Original Research Open access 13 January 2024 Pages: 257 - 268
Characteristics of COVID-19 and Impact of Disease Activity in Patients with Adult-Onset Still’s Disease Xinyue HongXiaoming WangHuihui Chi Brief Report Open access 06 January 2024 Pages: 201 - 212
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years Christina Charles-SchoemanJon T. GilesIain B. McInnes Original Research Open access 05 January 2024 Pages: 157 - 175
Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases and Serum Antibody Changes Post-Omicron Variant Infection Xiaowei ZhangYifei LiGuihong Wang Brief Report Open access 04 January 2024 Pages: 191 - 200
The Role of Early Treatment in the Management of Axial Spondyloarthritis: Challenges and Opportunities Daniele MauroGiulio ForteFrancesco Ciccia Review Open access 18 December 2023 Pages: 19 - 34
Adalimumab Effectively Decreases Inflammation Downstream of TNFα Signaling in Synoviocytes from Extended Oligoarticular Juvenile Idiopathic Arthritis Megan M. SimondsSamuel T. FreerAnneMarie C. Brescia Original Research Open access 09 December 2023 Pages: 143 - 155
Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis Jeffrey R. CurtisPaul EmeryGerd Rüdiger Burmester Brief Report Open access 06 December 2023 Pages: 177 - 189
Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis Gerd R. BurmesterLaura C. CoatesCassandra Kinch Correction Open access 02 December 2023 Pages: 221 - 222
Correction: Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis Jessica A. WalshChristopher D. SafforeAndrew Ostor Correction Open access 29 November 2023 Pages: 225 - 226
Correction: Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA) Siegfried WassenbergRolf RauPeter-Andreas Löschmann Correction Open access 29 November 2023 Pages: 215 - 215
Real-World Burden of Immunosuppressant-Treated Lupus Nephritis: A German Claims Database Analysis Elena Garal-PantalerMichael SchultzeJacob N. Hunnicutt Original Research Open access 25 November 2023 Pages: 113 - 127
Correction: Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study Christopher F. BellJake ChungBernard Rubin Correction Open access 23 November 2023 Pages: 219 - 219
Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate Yoshiya TanakaPeter C. TaylorTsutomu Takeuchi Correction Open access 20 November 2023 Pages: 223 - 224
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis Andrea Rubbert-RothAdriana M. KakehasiJeffrey R. Curtis Original Research Open access 20 November 2023 Pages: 97 - 112
Efficacy, Safety and the Lymphocyte Subset Changes of Low-Dose IL-2 in Patients with Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis Qinyi SuXinmiao WangSheng-Xiao Zhang Original Research Open access 19 November 2023 Pages: 79 - 96
Cross-Sectional and Longitudinal Associations of Comorbidities with Knee Symptoms and Radiographic Abnormalities of Osteoarthritis Xiaoxi LiFeng PanGuoqi Cai Original Research Open access 18 November 2023 Pages: 129 - 142
Correction: Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry Jeffrey R. CurtisHuifeng YunErnest Choy Correction Open access 13 November 2023 Pages: 217 - 217
Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid Arthritis Jeffrey R. CurtisVibeke StrandViatcheslav R. Akmaev Original Research Open access 10 November 2023 Pages: 61 - 77
Epidemiology of Sjögren’s: A Systematic Literature Review Eleanor ThurtleAlice GrosjeanPushpendra Goswami Review Open access 10 November 2023 Pages: 1 - 17
Endovascular Interventional Procedure is a Significant Risk Factor of Postsurgical Gout: A Retrospective Cohort Study Shunjie HuZitao WangXiaoyong Lu Original Research Open access 06 November 2023 Pages: 51 - 60
Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials Gustavo CiteraRakesh JainDario Ponce de Leon Original Research Open access 05 November 2023 Pages: 35 - 50
Serum Calprotectin as a Potential Predictor of Microvascular Manifestations in Patients with Antiphospholipid Syndrome Yuan ZhaoWanting QiJiuliang Zhao Original Research Open access 31 October 2023 Pages: 1769 - 1783
Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study Anisha B. DuaKerri FordAlan Kivitz Original Research Open access 31 October 2023 Pages: 1753 - 1768
Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study Mark S. FinemanTimothy E. McAlindonYusuf Yazici Original Research Open access 30 October 2023 Pages: 1741 - 1752
Pregnancy Outcomes in Patients with Primary Sjögren’s Syndrome Undergoing Assisted Reproductive Therapy: A Multi-center Retrospective Study Minxi LaoGuangxi LuoDongying Chen Original Research Open access 24 October 2023 Pages: 1725 - 1739
Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry Satoshi KuboYusuke MiyazakiYoshiya Tanaka Original Research Open access 19 October 2023 Pages: 1705 - 1723
Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1) Hideto KamedaKohei HagimoriHiroaki Dobashi Original Research Open access 19 October 2023 Pages: 1683 - 1703
A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis Laura C. CappelliGeorge ReedJoel M. Kremer Original Research Open access 19 October 2023 Pages: 1669 - 1681
Psoriasis and Psoriatic Arthritis Have a Major Impact on Quality of Life and Depressive Symptoms: A Cross-Sectional Study of 300 Patients Natalie FredeSonja HiestandNils Venhoff Original Research Open access 15 October 2023 Pages: 1655 - 1668
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study Philip J. MeaseDafna D. GladmanXenofon Baraliakos Original Research Open access 11 October 2023 Pages: 1637 - 1653
Targeting DORIS Remission and LLDAS in SLE: A Review Agner R. Parra SánchezRonald F. van VollenhovenAlessandro Sorrentino Review Open access 05 October 2023 Pages: 1459 - 1477
Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial Cory PeruginoEmma L. CulverJohn H. Stone Study Protocol Open access 04 October 2023 Pages: 1795 - 1808
Risk of Macrophage Activation Syndrome in Patients with Adult-Onset Still’s Disease Treated with IL-1 and IL-6 Inhibitors: A Meta-analysis and Single-Center Experience Soichiro AdachiKaoru Takase-MinegishiHideaki Nakajima Original Research Open access 04 October 2023 Pages: 1623 - 1636
Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study Chan-yuan WuQian WangXiao-feng Zeng Original Research Open access 28 September 2023 Pages: 1609 - 1622
Analysis of Factors Influencing Whole Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus in China Xuan HuangQing ShuYujie Zhou Original Research Open access 27 September 2023 Pages: 1597 - 1607
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients Rieke AltenGerd R. BurmesterBruno Fautrel Original Research Open access 27 September 2023 Pages: 1575 - 1595
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Alejandro BalsaSiegfried WassenbergPatrick Verschueren Original Research Open access 25 September 2023 Pages: 1555 - 1574
Association Between Mycophenolate Mofetil Use and Subsequent Infections Among Hospitalized Patients with Systemic Lupus Erythematosus: A Nested Case–Control Study Qingqing GuoXueyi ZhangZiyi Jin Original Research Open access 24 September 2023 Pages: 1535 - 1554
Correction: Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA) Siegfried WassenbergRolf RauPeter-Andreas Löschmann Correction Open access 20 September 2023 Pages: 213 - 213
A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis Leslie R. HarroldPatrick ZuegerPankaj A. Patel Original Research Open access 20 September 2023 Pages: 1519 - 1533
Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis Silvia ScriffignanoFabio Massimo PerrottaEnnio Lubrano Brief Report Open access 16 September 2023 Pages: 1785 - 1794
Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis Blanca Hernández-CruzUta KiltzFabrizio Conti Review Open access 16 September 2023 Pages: 1417 - 1457
Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice Stephanie G. WernerXenofon BaraliakosAxel J. Hueber Original Research Open access 11 September 2023 Pages: 1503 - 1518
Correction: Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes Eugen FeistXenofon BaraliakosPeter-Andreas Löschmann Correction Open access 05 September 2023 Pages: 1809 - 1810
Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses Yoshiya TanakaTsutomu TakeuchiVijay Rajendran Review Open access 05 September 2023 Pages: 1399 - 1415
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Philip J. MeaseAlexis OgdieJoseph F. Merola Original Research Open access 19 August 2023 Pages: 1479 - 1501
Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis Jessica A. WalshChristopher D. SafforeAndrew Ostor Original Research Open access 12 August 2023 Pages: 1385 - 1398
PDCD5 as a Potential Biomarker for Improved Prediction of the Incidence and Remission for Patients with Rheumatoid Arthritis Juan XiaoFengqiao ZhouAnbing Zhang Original Research Open access 01 August 2023 Pages: 1369 - 1383